New York, NY – December 18, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, will present at Biotech Showcase 2015 on Monday January 12, 2015 at 2:00pm PST. The investor and partnering conference will take place at the Parc 55 Wyndham San Francisco – Union Square.
President and Chief Executive Officer of Anavex, Christopher U. Missling, PhD, will provide a corporate overview including recent advancements of the Company’s Phase 2a clinical trial evaluating ANAVEX 2-73 and ANAVEX PLUS in Alzheimer’s patients.
Members of the investment community and attendees may also request one-on-one meetings with Dr. Missling and the Anavex management team at the conference by contacting email@example.com.
About ANAVEX 2-73 and ANAVEX PLUS
ANAVEX 2-73 is an orally available small molecule being investigated for the treatment of Alzheimer’s disease. In addition to preclinical data indicating that ANAVEX 2-73 has the potential to prevent, halt and/or reverse the course of Alzheimer’s disease, there was a highly encouraging synergistic effect observed between ANAVEX 2-73 and donepezil (Aricept®). The combined therapeutic, called ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.
About the Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS
The multicenter Phase 2a trial of ANAVEX 2-73 and ANAVEX PLUS is designed as an initial dose finding study of up to 36 days with an open-label extension study for an additional 26 weeks. The primary objective is to evaluate the maximum tolerated dose of ANAVEX 2-73 with ongoing administration in 32 mild to moderate Alzheimer’s patients. The open-label extension study is planned to establish a longer drug effect for patients who continue on an oral daily dose. The trial is expected to enroll patients at up to seven clinical sites in Melbourne, Australia. Additional trial objectives include dose response, bioavailability, cognitive efficacy and the relationship of ANAVEX 2-73 as an add-on therapy to donepezil, the current standard of care. Additional information is available from the U.S. National Institutes of Health (NIH) clinical trials database at www.clinicaltrials.gov.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat Alzheimer’s disease, other Central Nervous System (CNS) diseases, and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Further information is available at www.anavex.com.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development